Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 30

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 30
---
 Solutions product revenue. 

RMS operating income increased $5.8 million compared to the corresponding period in 2024. RMS operating income as a percentage of revenue for the three months ended June 28, 2025 was 16.8%, an increase of 230 bps from 14.5% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue increased primarily due to the increase in revenue described above coupled with lower asset impairment charges related to recent restructuring activities compared to the corresponding period in 2024.

29 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

DSA

Three Months EndedJune 28, 2025June 29, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$618,029 $627,419 $(9,390)(1.5)%1.1 %Cost of revenue (excluding amortization of intangible assets)421,907 418,964 2,943 0.7 %Selling, general and administrative60,270 54,479 5,791 10.6 %Amortization of intangible assets13,071 15,600 (2,529)(16.2)%Operating income$122,781 $138,376 $(15,595)(11.3)%1.1 %Operating income % of revenue19.9 %22.1 %(220) bps

DSA revenue decreased $9.4 million primarily due to lower volume driven by continued cautious client spending as a result of the current demand environment; partially offset by increases in pricing of offerings and the effect of changes in foreign currency exchange rates compared to the corresponding period in 2024.

DSA operating income decreased $15.6 million during the three months ended June 28, 2025 compared to the corresponding period in 2024. DSA operating income as a percentage of revenue for the three months ended June 28, 2025 was 19.9%, a decrease of 220 bps from 22.1% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue decreased primarily due to the lower revenue described above, restructuring activities including site consolidation and asset impairment charges, and certain third-party legal and advisory costs incurred in connection with the investigations by the U.S. government into the non-human primate supply chain, compared to the corresponding period in 2024.